DAWN Relative Valuation
DAWN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DAWN is overvalued; if below, it's undervalued.
Historical Valuation
Day One Biopharmaceuticals Inc (DAWN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.89 is considered Undervalued compared with the five-year average of -8.13. The fair price of Day One Biopharmaceuticals Inc (DAWN) is between 16.77 to 26.98 according to relative valuation methord. Compared to the current price of 6.63 USD , Day One Biopharmaceuticals Inc is Undervalued By 60.47%.
Relative Value
Fair Zone
16.77-26.98
Current Price：6.63
60.47%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.44
P/B
Median3y
3.32
Median5y
3.30
-13.04
FCF Yield
Median3y
-10.14
Median5y
-8.77
Competitors Valuation Multiple
The average P/S ratio for DAWN's competitors is 24.80, providing a benchmark for relative valuation. Day One Biopharmaceuticals Inc Corp (DAWN) exhibits a P/S ratio of 3.89, which is -84.31% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Day One Biopharmaceuticals Inc (DAWN) currently overvalued or undervalued?
What is Day One Biopharmaceuticals Inc (DAWN) fair value?
How does DAWN's valuation metrics compare to the industry average?
What is the current P/B ratio for Day One Biopharmaceuticals Inc (DAWN) as of Jul 08 2025?
What is the current FCF Yield for Day One Biopharmaceuticals Inc (DAWN) as of Jul 08 2025?
What is the current Forward P/E ratio for Day One Biopharmaceuticals Inc (DAWN) as of Jul 08 2025?